StockUS listing USVXRTNASDAQHealthcareQuality Compounder

Vaxart Inc(VXRT) Stock Analysis | Healthcare

USD --+0.00%
Reward61Moderate
Risk43Moderate
75%Data
Strong 16% profit margin · Revenue down 32% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 119.16M
Reward Ratingⓘ61 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ43 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on VXRT to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Vaxart Inc?

, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.

AI Brief Pro

The brief on Vaxart Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Vaxart Inc?

, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 119.16M, and a P/E ratio of 2.9x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (61)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap119.16M
P/E Ratio2.8824
Beta1.061
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.